Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 219 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Human Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

NCT02108639
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 6, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

NCT05304962
View directory record Official record
Conditions
Breast Cancer
Interventions
RGT-419B, RGT-419B in combination with hormonal therapy
Drug
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

NCT00095108
View directory record Official record
Conditions
Melanoma, Kidney Neoplasms, Metastases
Interventions
Recombinant Human Interleukin-21
Drug
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Oct 6, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117
View directory record Official record
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Completed No phase listed Observational

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

NCT05937776
View directory record Official record
Conditions
Glioma
Interventions
Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
BBI-940, Fulvestrant
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

NCT03901339
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06131398
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 355, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
ABBV-519
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Anniston, Alabama • Tustin, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions
KYV-101, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

NCT06188559
View directory record Official record
Conditions
Breast Cancer
Interventions
BB-1701
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Los Alamitos, California • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.

NCT01173627
View directory record Official record
Conditions
Pain
Interventions
Test fentanyl citrate 400 mcg troche, Actiq 400 mcg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 6, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single Photon Emission Computed Tomography of the Normal Human Brain

NCT01203891
View directory record Official record
Conditions
Normal Human Subjects
Interventions
Not listed
Lead sponsor
Amen Clinics, Inc.
Industry
Eligibility
10 Years to 90 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Oct 6, 2026, 5:22 AM EDT
Active, not recruiting Phase 1 Interventional

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT03401385
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
Drug · Other
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

NCT00168103
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 Esterase Inhibitor, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 6, 2026, 5:22 AM EDT
Not listed Phase 2 Interventional

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

NCT02640820
View directory record Official record
Conditions
Common Warts, HPV (Human Papillomavirus), Periungual Warts, Plantar Warts
Interventions
Sensitizing DPCP Ointment, Treatment DPCP Ointment
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Miami, Florida • Oakbrook Terrace, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

NCT03157167
View directory record Official record
Conditions
Kaposi Sarcoma, HIV Infections
Interventions
Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

NCT00545753
View directory record Official record
Conditions
Pediculosis
Interventions
Spinosad, Permethrin 1%
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months and older
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 6, 2026, 5:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

NCT05914116
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol

NCT00678834
View directory record Official record
Conditions
End Stage Cardiac Failure, Pulmonary Failure, End Stage Liver Disease, Morbid Obesity, Recalcitrant Epilepsy Requiring Surgery, Healthy Subjects
Interventions
To surgery patients, Tocopherol capsules., Tocotrienol to healthy subjects., To surgery patients, Tocotrienol capsules.
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 6, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

NCT00343187
View directory record Official record
Conditions
Rash, Non-small-Cell Lung Cancer
Interventions
ACZONE (dapsone) Gel, 5%, Vehicle Control
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Chicago, Illinois • Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 6, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 6, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Doxycycline in Humans

NCT00964834
View directory record Official record
Conditions
Anthrax
Interventions
Doxycycline and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 6, 2026, 5:22 AM EDT